SCHEMBL12765415

SCHEMBL12765415

COC(=O)CCCS(=O)(=O)NC(=O)C(C)c1cccc(C(=O)c2ccccc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 3/20 0.55
PTGS2 P35354 3/20 0.55
CA12 O43570 5/20 0.50
CA1 P00915 5/20 0.50
CA2 P00918 5/20 0.50
CA4 P22748 5/20 0.50
CA9 Q16790 5/20 0.50
MAPT P10636 5/20 0.50
ALDH1A1 P00352 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
LMNA P02545 3/20 0.50
CXCR1 P25024 2/20 0.50
CXCR2 P25025 2/20 0.50
CYP3A4 P08684 2/20 0.50
RECQL P46063 1/20 0.50
KDM4E B2RXH2 1/20 0.50
HPGD P15428 1/20 0.50
MAPK1 P28482 1/20 0.50
PMP22 Q01453 1/20 0.50
SLC22A6 Q4U2R8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3979139 0.90 MAPT (0.53) PTGS1PTGS2CA12CA1CA2
SCHEMBL1519613 0.90 PTGS1 (0.41) PTGS1PTGS2CA12CA1CA2
SCHEMBL1519474 0.87 PTGS1 (0.50) PTGS1PTGS2CA12CA1CA2
SCHEMBL12837394 0.87 MAPT (0.54) PTGS1PTGS2CA12CA1CA2
SCHEMBL1519369 0.86 MAPT (0.51) PTGS1PTGS2CA12CA1CA2
SCHEMBL13274249 0.85 MAPT (0.52) PTGS1PTGS2CA12CA1CA2
SCHEMBL13274415 0.84 MAPT (0.51) PTGS1PTGS2CA12CA1CA2
SCHEMBL7011092 0.83 CA12 (0.57) PTGS1PTGS2CA12CA1CA2
SCHEMBL6315710 0.83 CA12 (0.57) PTGS1PTGS2CA12CA1CA2
SCHEMBL15486527 0.83 MAPT (0.61) PTGS1PTGS2CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897560-B2 Plasma protein affinity tags NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
US-20100184641-A1 Novel Plasma Protein Affinity Tags NOVO NORDISK A/S (DK) 2010-07-22 US disclosed
US-20100184641-A1 Novel Plasma Protein Affinity Tags NOVO NORDISK A/S (DK) 2010-07-22 US disclosed
US-7541430-B2 Peptides for use in treating obesity NOVO NORDISK A/S (DK) 2009-06-02 US disclosed
US-20090088388-A1 Peptides for Use In Treating Obesity NOVO NORDISK A/S (DK) 2009-04-02 US disclosed
US-20070244054-A1 Peptides for use in treating obesity NOVO NORDISK A/S (DK) 2007-10-18 US disclosed
US-20070244054-A1 Peptides for use in treating obesity NOVO NORDISK A/S (DK) 2007-10-18 US disclosed
US-20070105750-A1 Novel plasma protein affinity tags NOVO NORDISK A/S (DK) 2007-05-10 US disclosed
US-20070105750-A1 Novel plasma protein affinity tags NOVO NORDISK A/S (DK) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184641-A1 Novel Plasma Protein Affinity Tags CD2BP2, HDLBP, SERPINA6 PTGS1 4520/4885PTGS2 4581/4885CA12 4761/4885
US-20070105750-A1 Novel plasma protein affinity tags CD2BP2, HDLBP, SERPINA6 PTGS1 4520/4885PTGS2 4581/4885CA12 4761/4885
US-20070244054-A1 Peptides for use in treating obesity NPY4R, GLP1R, NPY1R PTGS1 3932/4885PTGS2 4649/4885CA12 3488/4885
US-20090088388-A1 Peptides for Use In Treating Obesity NPY4R, GLP1R, NPY1R PTGS1 3932/4885PTGS2 4649/4885CA12 3488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.